These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12297365)

  • 1. Ex vivo serum activity (killing rates) after gemifloxacin 320 mg versus trovafloxacin 200 mg single doses against ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae.
    Calvo A; Giménez MJ; Alou L; Gómez-Lus ML; Aguilar L; Prieto J
    Int J Antimicrob Agents; 2002 Aug; 20(2):144-6. PubMed ID: 12297365
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.
    Prieto J; Aguilar L; Fuentes F; Giménez MJ; Alou L; Dal-Ré R; Sörgel F; Frías J
    Int J Antimicrob Agents; 2001 Sep; 18(3):231-8. PubMed ID: 11673035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae.
    Joyanes P; Pascual A; Giménez MJ; García I; Aguilar L; Perea E
    Chemotherapy; 2001 Dec; 47(6):409-14. PubMed ID: 11786655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility.
    García-Olmos M; Parra A; García-Calvo G; Ponte C; Giménez MJ; Aguilar L; Soriano F
    Int J Antimicrob Agents; 2003 Jun; 21(6):568-73. PubMed ID: 12791471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
    Evans ME
    Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):883-5. PubMed ID: 11837640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal activity of gemifloxacin and other quinolones against Streptococcus pneumoniae.
    Morrissey I; George JT
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():107-10. PubMed ID: 10824041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.
    Fuentes F; Giménez MJ; Marco F; Alou L; Aguilar L; Prieto J
    Eur J Clin Microbiol Infect Dis; 2000 Feb; 19(2):137-9. PubMed ID: 10746503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of gemifloxacin (SB-265805) compared to eleven other antimicrobial agents against streptococcal isolates, excluding Streptococcus pneumoniae.
    Kerawala M; Ambler JE; Lee PY; Drabu YJ
    Eur J Clin Microbiol Infect Dis; 2001 Apr; 20(4):271-5. PubMed ID: 11399019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.
    Heaton VJ; Goldsmith CE; Ambler JE; Fisher LM
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2998-3000. PubMed ID: 10582896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bactericidal activity of gemifloxacin (SB-265805).
    Morrissey I; Clark S; Mathias I
    J Med Microbiol; 2000 Sep; 49(9):841-844. PubMed ID: 10966234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.
    García-Garrote F; Cercenado E; Martín-Pedroviejo J; Cuevas O; Bouza E
    J Antimicrob Chemother; 2001 May; 47(5):681-4. PubMed ID: 11328784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antistaphylococcal and antistreptococcal killing kinetics of ciprofloxacin, ofloxacin, sparfloxacin, and trovafloxacin.
    Prenna M; Montanari MP; Mingoia M; Biavasco F; Ripa S; Varaldo PE
    Eur J Clin Microbiol Infect Dis; 1998 Nov; 17(11):816-9. PubMed ID: 9923533
    [No Abstract]   [Full Text] [Related]  

  • 15. Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae.
    Schmitz FJ; Boos M; Mayer S; Hafner D; Jagusch H; Verhoef J; Fluit AC
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2666-7. PubMed ID: 11523528
    [No Abstract]   [Full Text] [Related]  

  • 16. Activity of gemifloxacin against invasive and multi-resistant Streptococcus pneumoniae isolates collected in the UK.
    Johnson AP; Warner M; Nguyen-Van-Tam JS; Livermore DM
    J Antimicrob Chemother; 2003 Jan; 51(1):188-90. PubMed ID: 12493813
    [No Abstract]   [Full Text] [Related]  

  • 17. Activity of gemifloxacin, a new broad-spectrum quinolone, against 200 pneumococci by four different susceptibility testing methods.
    Ednie LM; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2000 Apr; 45(4):525-8. PubMed ID: 10747832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activity of gemifloxacin.
    King A; May J; French G; Phillips I
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():1-12. PubMed ID: 10824026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis.
    Cottagnoud P; Acosta F; Cottagnoud M; Täuber MG
    Antimicrob Agents Chemother; 2002 May; 46(5):1607-9. PubMed ID: 11959614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones.
    Morrissey I; George JT
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():101-6. PubMed ID: 10824040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.